Jazz Pharmaceuticals plc Just Beat Earnings Expectations: Here’s What Analysts Think Will Happen Next
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) investors will be delighted, with the company turning in some strong numbers with its latest results. The company beat forecasts, with revenue of US$1.1b, some 9.2% above estimates, and statutory earnings per share (EPS) coming in at US$4.43, 142% ahead of expectations. This is an important time for investors, as they can track a company’s performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. With this in mind, we’ve gathered the latest statutory forecasts to see what the analysts are expecting for next year.
Taking into account the latest results, Jazz Pharmaceuticals’ 16 analysts currently expect revenues in 2026 to be US$4.49b, approximately in line with the last 12 months. Statutory earnings per share are predicted to surge 2,816% to US$13.69. In the lead-up to this report, the analysts had been modelling revenues of US$4.45b and earnings per share (EPS) of US$12.56 in 2026. The analysts seems to have become more bullish on the business, judging by their new earnings per share estimates.
Check out our latest analysis for Jazz Pharmaceuticals
The analysts have been lifting their price targets on the back of the earnings upgrade, with the consensus price target rising 7.1% to US$242. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. There are some variant perceptions on Jazz Pharmaceuticals, with the most bullish analyst valuing it at US$281 and the most bearish at US$188 per share. Analysts definitely have varying views on the business, but the spread of estimates is not wide enough in our view to suggest that extreme outcomes could await Jazz Pharmaceuticals shareholders.
Of course, another way to look at these forecasts is to place them into context against the industry itself. It’s pretty clear that there is an expectation that Jazz Pharmaceuticals’ revenue growth will slow down substantially, with revenues to the end of 2026 expected to display 1.6% growth on an annualised basis. This is compared to a historical growth rate of 8.8% over the past five years. Compare this against other companies (with analyst forecasts) in the industry, which are in aggregate expected to see revenue growth of 8.8% annually. Factoring in the forecast slowdown in growth, it seems obvious that Jazz Pharmaceuticals is also expected to grow slower than other industry participants.
The Bottom Line
The most important thing here is that the analysts upgraded their earnings per share estimates, suggesting that there has been a clear increase in optimism towards Jazz Pharmaceuticals following these results. Fortunately, the analysts also reconfirmed their revenue estimates, suggesting that it’s tracking in line with expectations. Although our data does suggest that Jazz Pharmaceuticals’ revenue is expected to perform worse than the wider industry. There was also a nice increase in the price target, with the analysts clearly feeling that the intrinsic value of the business is improving.
With that said, the long-term trajectory of the company’s earnings is a lot more important than next year. We have estimates – from multiple Jazz Pharmaceuticals analysts – going out to 2028, and you can see them free on our platform here.
It is also worth noting that we have found 4 warning signs for Jazz Pharmaceuticals that you need to take into consideration.
New: Manage All Your Stock Portfolios in One Place
We’ve created the ultimate portfolio companion for stock investors, and it’s free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
